ROCKVILLE, Md., Sept. 3, 2014 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE MKT: SYN), a developer of novel
anti-infective biologic and drug candidates targeting specific
pathogens that cause serious infections and diseases, announced
today that Jeffrey Riley, CEO, is
scheduled to present at the 16th Annual Rodman &
Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. Mr. Riley is
scheduled to present at 10:25 a.m. (Eastern
Time) on Tuesday, September 9,
2014 at the New York Palace Hotel in New York City.
A live webcast of Synthetic Biologics' presentation may be
accessed by logging onto the internet at
http://wsw.com/webcast/rrshq24/syn. After the presentation, a
replay will be archived and accessible for 30 days at the same
website.
Mr. Riley, as well as Synthetic Biologics' CFO, C. Evan Ballantyne, will be available to
participate in one-on-one meetings with investors and analysts who
are registered to attend the conference. If you are an
institutional investor, and would like to attend the Company's
presentation, please register for the Rodman & Renshaw
conference using the following link www.rodm.com. Once your
registration is confirmed, you will be prompted to log into the
conference website and may request a one-on-one meeting with the
Company.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology
company focused on the development of novel anti-infective biologic
and drug candidates targeting specific pathogens that cause serious
infections and diseases. The Company is developing an oral biologic
to protect the gastrointestinal microflora from the effects of IV
antibiotics for the prevention of Clostridium difficile (C.
difficile) infection, an oral treatment to reduce the impact of
methane producing organisms on constipation-predominant irritable
bowel syndrome (C-IBS), a series of monoclonal antibodies for the
treatment of Pertussis and Acinetobacter infections, and a
biologic targeted at the prevention and treatment of a root cause
of a subset of IBS. In addition, the Company is developing an oral
estriol drug for the treatment of relapsing-remitting multiple
sclerosis (MS) and cognitive dysfunction in MS. For more
information, please visit Synthetic Biologics' website at
www.syntheticbiologics.com.
Logo -
http://photos.prnewswire.com/prnh/20130522/MM19465LOGO
SOURCE Synthetic Biologics, Inc.